Payment overview · 2025
General Payments
$10,579.93
143 reported records · 13 companies
Healthcare provider profile · identity verified
Steven Kong
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BROOKLYN, NY · NPI 1407142052
Verified facts
What the public records show
CMS Open Payments records show Steven Kong received $10,579.93 in general payments during 2025 across 143 reported records.
Gilead Sciences, Inc. accounted for 68.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Kerendia, Linzess, Nexletol, Nurtec Odt, Prolia, Vemlidy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 477 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 1306 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Vemlidy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $7,289.81 | 68.9% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $948.91 | 9.0% | 26 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $484.35 | 4.6% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $352.43 | 3.3% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $289.18 | 2.7% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $265.08 | 2.5% | 26 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $252.15 | 2.4% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $247.98 | 2.3% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $210.46 | 2.0% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $151.61 | 1.4% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.57 | 0.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.73 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.67 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,510.00 | 7 |
| Food and Beverage | $4,069.93 | 136 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $1,055.00 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $435.72 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $339.90 | 16 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $284.56 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $267.75 | 11 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $265.08 | 26 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $252.15 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $247.98 | 2 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $210.46 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $206.23 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $173.29 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $151.61 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $133.15 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $129.12 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $129.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $129.06 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.87 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.57 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 152 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 477 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 75 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 1306 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 25 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 115 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 195 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
151 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
115 | 83 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
477 | 65 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
1306 | 175 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
195 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
232 | 42 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 2539 | 315 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2165 | 260 |
| Losartan Potassium | Losartan Potassium | 1517 | 170 |
| Nexletol | Bempedoic Acid | 1306 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 1260 | 138 |
| Donepezil Hcl | Donepezil Hcl | 899 | 114 |
| Metformin Hcl | Metformin Hcl | 879 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 827 | 100 |
| Omeprazole | Omeprazole | 728 | 136 |
| Meclizine Hcl | Meclizine Hcl | 719 | 142 |
| Halobetasol Propionate | Halobetasol Propionate | 694 | 149 |
| Naproxen | Naproxen | 588 | 151 |
| Dexlansoprazole Dr | Dexlansoprazole | 587 | 101 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 578 | 60 |
| Gabapentin | Gabapentin | 551 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 537 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 504 | 150 |
| Allopurinol | Allopurinol | 497 | 55 |
| Mirtazapine | Mirtazapine | 493 | 100 |
| Ammonium Lactate | Ammonium Lactate | 485 | 96 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 479 | 86 |
| Farxiga | Dapagliflozin Propanediol | 477 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 474 | 55 |
| Celecoxib | Celecoxib | 472 | 87 |
| Finasteride | Finasteride | 462 | 51 |
| Simvastatin | Simvastatin | 447 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 405 | 99 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 388 | 64 |
| Xarelto | Rivaroxaban | 387 | 41 |
| Januvia | Sitagliptin Phosphate | 381 | 41 |
| Montelukast Sodium | Montelukast Sodium | 369 | 49 |
| Mometasone Furoate | Mometasone Furoate | 362 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 349 | 109 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 335 | 85 |
| Trazodone Hcl | Trazodone Hcl | 332 | 49 |
| Jardiance | Empagliflozin | 327 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 327 | 72 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 326 | 71 |
| Bepotastine Besilate | Bepotastine Besilate | 321 | 75 |
| Atenolol | Atenolol | 304 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 51 |
| Alendronate Sodium | Alendronate Sodium | 281 | 32 |
| Ibuprofen | Ibuprofen | 278 | 171 |
| Glipizide Er | Glipizide | 267 | 27 |
| Azelastine Hcl | Azelastine Hcl | 258 | 59 |
| Alcohol Pads | Alcohol Antiseptic Pads | 246 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 25 |
| Trulance | Plecanatide | 232 | 42 |
| Colchicine | Colchicine | 223 | 27 |
| Icosapent Ethyl | Icosapent Ethyl | 199 | 108 |
| Tacrolimus | Tacrolimus | 197 | 42 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 195 | 56 |
| Vemlidy | Tenofovir Alafenamide | 195 | 26 |
| Azithromycin | Azithromycin | 184 | 123 |
| Rivastigmine | Rivastigmine | 177 | 25 |
| Ketoconazole | Ketoconazole | 173 | 31 |
| Diclofenac Epolamine | Diclofenac Epolamine | 172 | 94 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 161 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 159 | 16 |
| Meloxicam | Meloxicam | 156 | 25 |
| Rybelsus | Semaglutide | 154 | 18 |
| Creon | Lipase/Protease/Amylase | 152 | 27 |
| Restasis | Cyclosporine | 151 | 28 |
| Synthroid | Levothyroxine Sodium | 151 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 149 | 107 |
| Procto-Med Hc | Hydrocortisone | 140 | 33 |
| Famotidine | Famotidine | 137 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 131 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 11 |
| Metformin Hcl Er | Metformin Hcl | 119 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 115 | 11 |
| Prolia | Denosumab | 115 | 83 |
| Hydrocortisone | Hydrocortisone | 113 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 34 |
| Nebivolol Hcl | Nebivolol Hcl | 110 | 12 |
| Metformin Er Gastric | Metformin Hcl | 109 | 38 |
| Nexium | Esomeprazole Magnesium | 106 | 24 |
| Eliquis | Apixaban | 104 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 104 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 96 | 20 |
| Gemfibrozil | Gemfibrozil | 96 | 11 |
| Ezetimibe | Ezetimibe | 90 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 90 | 11 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 88 | 25 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 88 | 33 |
| Sucralfate | Sucralfate | 88 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 83 | 32 |
| Ursodiol | Ursodiol | 83 | suppressed |
| Amoxicillin | Amoxicillin | 82 | 60 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 80 | 20 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 79 | 30 |
| Acarbose | Acarbose | 77 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 18 |
| Glipizide | Glipizide | 75 | suppressed |
| Linzess | Linaclotide | 75 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 59 |
| Tradjenta | Linagliptin | 73 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 72 | 16 |
| Fluocinonide | Fluocinonide | 72 | 21 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 71 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Lisinopril | Lisinopril | 66 | suppressed |
| Scopolamine | Scopolamine | 66 | 22 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 63 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 62 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | suppressed |
| Ozempic | Semaglutide | 59 | 13 |
| Furosemide | Furosemide | 58 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | suppressed |
| Ranolazine Er | Ranolazine | 58 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 56 | suppressed |
| Loperamide | Loperamide Hcl | 56 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Ciclopirox | Ciclopirox | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 37 |
| Baclofen | Baclofen | 47 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Entecavir | Entecavir | 46 | suppressed |
| Proctozone-Hc | Hydrocortisone | 46 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Dexilant | Dexlansoprazole | 45 | 19 |
| Dutasteride | Dutasteride | 45 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 23 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 43 | suppressed |
| Xiidra | Lifitegrast | 43 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 41 | 13 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 30 |
| Carvedilol | Carvedilol | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 34 | 18 |
| Acyclovir | Acyclovir | 33 | 15 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 16 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Livalo | Pitavastatin Calcium | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 29 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 14 |
| Folic Acid | Folic Acid | 27 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 11 |
| Fluconazole | Fluconazole | 25 | 20 |
| Nurtec Odt | Rimegepant Sulfate | 25 | 12 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 19 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Desloratadine | Desloratadine | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 20 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ibu | Ibuprofen | 19 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Bystolic | Nebivolol Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Prednisone | Prednisone | 18 | 11 |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Desoximetasone | Desoximetasone | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Zileuton Er | Zileuton | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Mupirocin | Mupirocin Calcium | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Flarex | Fluorometholone Acetate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,579.93 · 143 records | Gilead Sciences, Inc. | AIRSUPRA, BREZTRI, CREON, EVENITY, FARXIGA, IBSRELA, Kerendia, LAGEVRIO, LINZESS, Livdelzi, NEMLUVIO, NEXLETOL, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, REZDIFFRA, UBRELVY, VOQUEZNA, VYALEV, Vemlidy, XGEVA, XIFAXAN, Yeztugo, ZAVZPRET | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error